1-2 of 2
Victor J Jimenez Zepeda
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity.

Craig B. Reeder, MD, Donna E. Reece, Vishal Kukreti, MD, FRCPC, Joseph R. Mikhael, MD, Christine Chen, MD, Suzanne Trudel, MD, Kristina Laumann, Joseph Hentz, Nick Pirooz, Jg Piza, MD, Victor J Jimenez Zepeda, Rafael Fonseca, P. Leif Bergsagel, Jose Leis, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, A. Keith Stewart, MBChB
Journal: Blood
Blood (2009) 114 (22): 616.
https://doi.org/10.1182/blood.V114.22.616.616
Published: 2009
Journal Articles

Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.

Soledad Molnar, MD, Victor J Jimenez Zepeda, Scott Van Wier, Esteban Braggio, Jonathan Keats, Michael Kuehl, Tammy Price-Troska, Greg Ahmann, Rachel Rempel, Kim Henderson, MD, S. Vincent Rajkumar, MD, Philip. R Greipp, MD, Daniel Auclair, John Carpten, Angela Baker, Keith Stewart, MD, P. Leif Bergsagel, MD, Wee Joo Chng, MD, Rafael Fonseca, MD
Journal: Blood
Blood (2008) 112 (11): 1663.
https://doi.org/10.1182/blood.V112.11.1663.1663
Published: 2008